MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 7, 2008; DOI: 10.1124/mol.108.046029


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.046029v1
74/2/496    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borner, C.
Right arrow Articles by Hollt, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borner, C.
Right arrow Articles by Hollt, V.


Received for publication February 5, 2008.
Revised April 28, 2008.
Accepted for publication May 7, 2008.

T cell receptor/CD28-mediated activation of human T lymphocytes induces expression of functional µ-opioid receptors

Christine Borner 1, Juergen Kraus 2*, Andrea Bedini 1, Burkhart Schraven 3, Volker Hollt 1

1 University of Magdeburg, Dept. of Pharmacology 2 University of Magdeburg 3 University of Magdeburg, Dept. of Immunology

* Address correspondence to: E-mail: juergen.kraus{at}medizin.uni-magdeburg.de

Abstract

Opiates function as immunomodulators, partly by effects on T cells. Opioids act via µ-, {delta}- and {kappa}-opioid receptors, among which the µ-type is of particular interest, since morphine-like opioids preferentially bind to it. Here we report that µ-opioid receptor mRNA was induced after CD3/28-mediated activation of primary human T lymphocytes and Jurkat T cells, which both do not express the gene constitutively. Moreover, a reporter gene construct containing 2624 bp of the µ-opioid receptor promoter was trans-activated by CD3/28-stimulation. Transcriptional induction of the µ-opioid receptor gene was mediated by AP-1, NF-{kappa}B and NFAT. NFAT was found to bind to three sequences of the µ-opioid receptor promoter, located at nucleotides -1064, -785 and -486. Although the -486 element is in close proximity to a putative AP-1 site, there was no evidence for a combined AP-1/NFAT site. Furthermore, we demonstrated that the induction of interleukin-2 mRNA and protein in activated T cells was inhibited by morphine in cells, in which µ-opioid receptors had been induced by CD3/28 mAbs and that this effect was blocked by the µ-opioid receptor-specific antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP). CD3/28 mAbs-induced interleukin-2 transcription was also inhibited by the opioids fentanyl and loperamide. This indicates that the induced µ-opioid receptor mRNA is translated into functional receptor protein. Furthermore, a µ-opioid receptor-enhanced green fluorescent protein-fusion protein was localized in membranes of Jurkat cells and internalized in response to [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin (DAMGO), but not morphine. In conclusion, these data emphazise the role of opioids in the modulation of T lymphocyte signaling.


Key words: Opioid, AP-1, NFAT, NFkappaB, DNA binding sites, Promoter analysis, Regulation of gene expression, Regulation - transcriptional





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics